{
    "clinical_study": {
        "@rank": "51827", 
        "acronym": "CLIN01", 
        "arm_group": {
            "arm_group_label": "Clindamycin", 
            "arm_group_type": "Active Comparator", 
            "description": "Clindamycin phosphate (intravenous) Clindamycin hydrochloride (oral capsules) Clindamycin palmitate (oral solution)\nSchedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is better understand how clindamycin works in children who fall in\n      the 85th percentile or higher for body mass index (a ratio of weight to height).  The\n      results of the study will help better understand if children in higher BMI ranges process\n      the medication differently and whether dosing should be adjusted in these children."
        }, 
        "brief_title": "Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI \u2265 85th Percentile", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Bacterial Infections", 
            "Obesity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bacterial Infections", 
                "Obesity"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, open-label pharmacokinetic and safety study of multiple doses of IV\n      and oral clindamycin in overweight and obese children 2 - < 18 years of age. The total study\n      duration is expected to be approximately 24 months; each subject will participate in the\n      study for up to 18 days (screening day; treatment days 1-14 [may be as short as 2 days]\n      followed by an observation period of 3 days post discontinuation of clindamycin therapy or\n      after day 17 (on day 18) of therapy in those who are treated with more than 14 days of\n      clindamycin)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  2 years - < 18 years of age at the time of first dose of study drug\n\n          -  Suspected or confirmed infection OR receiving IV clindamycin per routine care\n\n          -  Negative serum pregnancy test (if female and has reached menarche) within 24 hours of\n             first dose of study drug and agreement to practice appropriate contraceptive\n             measures, including abstinence, from the time of the initial pregnancy test through\n             the last dose of study drug\n\n          -  BMI \u2265 85th percentile for age and sex, based on Centers for Disease Control (CDC)\n             recommendations\n\n          -  Signed informed consent/Health Insurance Portability and Accountability Act (HIPAA)\n             documents by the parent/legal guardian and assent (if applicable)\n\n        Exclusion Criteria:\n\n          -  The following apply only to those who are NOT already receiving clindamycin per\n             routine care:\n\n               1. History of hypersensitivity or allergic reaction to clindamycin or lincomycin\n\n               2. History of C. difficile colitis with previous administration of clindamycin\n\n               3. Aspartate aminotransferase (AST) > 120 units/L\n\n               4. Alanine aminotransferase (ALT) > 210 units/L\n\n               5. Total bilirubin > 3 mg/dL\n\n               6. Serum creatinine > 2 mg/dL\n\n               7. Receiving a neuromuscular blocker as part of their therapy\n\n          -  Previous participation in the study\n\n          -  Subject is on prohibited medication or herbal product (see Appendix II)\n\n          -  Subject is receiving extracorporeal life support (ECLS)\n\n          -  Subject is post-cardiac bypass (within 24 hours)\n\n          -  Subject on inotropes/pressors\n\n          -  Any other condition or chronic illness that, in the opinion of the principal\n             investigator, makes participation unadvised or unsafe"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01744730", 
            "org_study_id": "Pro00041855", 
            "secondary_id": "HHSN275201000003I"
        }, 
        "intervention": {
            "arm_group_label": "Clindamycin", 
            "description": "Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.", 
            "intervention_name": "Clindamycin", 
            "intervention_type": "Drug", 
            "other_name": [
                "Clindamycin phosphate (intravenous)", 
                "Clindamycin hydrochloride (oral capsules)", 
                "Clindamycin palmitate (oral solution)"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Clindamycin", 
                "Clindamycin-2-phosphate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Bacterial infections", 
            "Obesity", 
            "pharmacokinetics", 
            "clindamycin"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "link": [
            {
                "description": "Pediatric Trials Network", 
                "url": "https://pediatrictrials.org/"
            }, 
            {
                "description": "National Institute for Child Health and Human Development", 
                "url": "http://www.nichd.nih.gov/Pages/index.aspx"
            }
        ], 
        "location": {
            "contact": {
                "last_name": "Michael J Smith, MD, MSCE"
            }, 
            "facility": {
                "address": {
                    "city": "Louisville", 
                    "country": "United States", 
                    "state": "Kentucky", 
                    "zip": "40202"
                }, 
                "name": "University of Louisville"
            }, 
            "investigator": {
                "last_name": "Michael J Smith, MD, MSCE", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Pharmacokinetics of Multiple-Dose Intravenous and Oral Clindamycin in Pediatric Subjects With BMI \u2265 85th Percentile (NICHD): CLIN01", 
        "overall_contact": {
            "email": "brian.smith@dm.duke.edu", 
            "last_name": "P. Brian Smith, MD, MHS, MPH", 
            "phone": "919-668-8951"
        }, 
        "overall_contact_backup": {
            "email": "kevin.watt@dm.duke.edu", 
            "last_name": "Kevin Watt, MD", 
            "phone": "919-668-8556"
        }, 
        "overall_official": [
            {
                "affiliation": "Duke Medical Center/Duke Clinical Research Institute", 
                "last_name": "P. Brian Smith, MD, MHS, MPH", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Duke Medical Center/Duke Clinical Research Institute", 
                "last_name": "Kevin Watt, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Louisville", 
                "last_name": "Michael J Smith, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Data and Safety Monitoring Board", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The PK schedule will be as follows:\nPre-dose 0 (within 15 minutes prior to the dose) 0.5 (\u00b1 5 minutes) 1-1.5 hrs 3-4 hrs 5-6 hrs", 
                "measure": "Clearance (Cl)", 
                "safety_issue": "No", 
                "time_frame": "A population PK analysis will be done so multiple timeframes will be included (0 hr; 0.5 hr; 1-1.5 hr; 3-4 hr and 5-6 hr post-dose)"
            }, 
            {
                "description": "The PK schedule will be as follows:\nPre-dose 0 (within 15 minutes prior to the dose) 0.5 (\u00b1 5 minutes) 1-1.5 hrs 3-4 hrs 5-6 hrs", 
                "measure": "Volume of distribution (Vd)", 
                "safety_issue": "No", 
                "time_frame": "A population PK analysis will be done so multiple timeframes will be included (0 hr; 0.5 hr; 1-1.5 hr; 3-4 hr and 5-6 hr post-dose)"
            }, 
            {
                "description": "The PK schedule will be as follows:\nPre-dose 0 (within 15 minutes prior to the dose) 0.5 (\u00b1 5 minutes) 1-1.5 hrs 3-4 hrs 5-6 hrs", 
                "measure": "Area under the curve (AUCtau)", 
                "safety_issue": "No", 
                "time_frame": "A population PK analysis will be done so multiple timeframes will be included (0 hr; 0.5 hr; 1-1.5 hr; 3-4 hr and 5-6 hr post-dose)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01744730"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Duke University Medical Center", 
            "investigator_full_name": "Phillip Brian Smith", 
            "investigator_title": "Associate Professor of Pediatrics", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The PK schedule will be as follows:\nPre-dose 0 (within 15 minutes prior to the dose) 0.5 (\u00b1 5 minutes) 1-1.5 hrs 3-4 hrs 5-6 hrs", 
                "measure": "Oral apparent clearance (Cl/F)", 
                "safety_issue": "No", 
                "time_frame": "A population PK analysis will be done so multiple timeframes will be included (0 hr; 0.5 hr; 1-1.5 hr; 3-4 hr and 5-6 hr post-dose)"
            }, 
            {
                "description": "The PK schedule will be as follows:\nPre-dose 0 (within 15 minutes prior to the dose) 0.5 (\u00b1 5 minutes) 1-1.5 hrs 3-4 hrs 5-6 hrs", 
                "measure": "Oral apparent volume of distribution (V/F)", 
                "safety_issue": "No", 
                "time_frame": "A population PK analysis will be done so multiple timeframes will be included (0 hr; 0.5 hr; 1-1.5 hr; 3-4 hr and 5-6 hr post-dose)"
            }, 
            {
                "measure": "Number of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "First dose of study medication to 3 days after last dose of study medication"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Phillip Brian Smith", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}